Dr Reddy's Laboratories Share Price
(DRREDDY)
Check the latest share price of Dr Reddy's Laboratories, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
₹1176
as on 04:01PM, 29 Apr 2025
NSE
Dr Reddy's Laboratories Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,169Day's Price Range₹1,204.452 Week's Low
52 Week's High
₹1,02052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | -3.58 % |
| 3 Month Return | -17.03 % |
| 1 Year Return | -7.71 % |
| Market Stats | |
| Previous Close | ₹1,198.70 |
| Open | ₹1,204.40 |
| Volume | 16.63L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹92,582.82Cr |
Dr Reddy's Laboratories Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹92,582.82 Cr
Return on Equity (ROE)
9.19
Return on capital employed (ROCE)
11.63
P/B Ratio
3.87
Dividend Yield
0.7
EPS (TTM)
131.16
Sector
Pharmaceuticals
How to invest in Dr Reddy's Laboratories
Investing in Dr Reddy's Laboratories is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Dr Reddy's Laboratories or DRREDDY on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Dr Reddy's Laboratories or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Dr Reddy's Laboratories with just a few clicks!
Dr Reddy's Laboratories Valuation
Track how the P/E of Dr Reddy's Laboratories has moved over time to understand valuation trends.
Dr Reddy's Laboratories in the last 5 years
Lowest (15.84x)
October 7, 2019
Industry (58.33x)
December 15, 2023
Today (91.23x)
December 15, 2023
Highest (269.38x)
December 18, 2020
Today’s Price to Earnings Ratio: 91.23x
Analysts Recommendation on Dr Reddy's Laboratories
Get updated buy, sell, and hold recommendations by analysts on Dr Reddy's Laboratories.
based on 38 analysts
47.37%
Buy
26.32%
Hold
26.32%
Sell
47.37% of analysts recommend a 'BUY' rating for Dr Reddy's Laboratories. Average target of ₹5563.37
Source: S&P Global Market Intelligence
Analysts Forecast on Dr Reddy's Laboratories
Get share price movements and forecasts by analysts on Dr Reddy's Laboratories.
Dr Reddy's Laboratories price forecast by 38 analysts
Upside of401.43%
High
₹6560
Target
₹5563.37
Low
₹3794
Dr Reddy's Laboratories target price ₹5563.37, a slight upside of 401.43% compared to current price of ₹1176. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2025:18.26%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2025:13.83%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Financials
Get the annual and quarterly financial summary of Dr Reddy's Laboratories, including revenue, profit, loss and more.
Dr Reddy's Laboratories Index Inclusions
Dr Reddy's Laboratories Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Dr Reddy's Laboratories.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.7% | 0.00 | |
| Foreign Institutions | 27.25% | 0.00 | |
| Mutual Funds | 9.87% | 0.00 | |
| Retail Investors | 11.48% | 0.00 | |
| Others | 24.7% | 0.00 |
Dr Reddy's Laboratories vs Peers
Compare market cap, revenue, PE, and other key metrics of Dr Reddy's Laboratories with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹92,582.82 Cr | 9.14% | 0.56 | NA | NA | |
| HOLD | ₹1,48,378.35 Cr | 26.67% | 0.50 | NA | NA | |
| BUY | ₹1,05,894.82 Cr | 34.5% | 0.68 | NA | NA | |
| BUY | ₹38,004.99 Cr | -1.21% | 0.51 | NA | NA | |
| HOLD | ₹22,962.93 Cr | -4.68% | 0.50 | NA | NA |
Dr Reddy's Laboratories News & Key Events
Latest news and events at one place to help you take investing decisions in Dr Reddy's Laboratories.
Dr. Reddys Expands Partnership to Launch Beyfortus - 28 Apr, 2025
Dr. Reddys Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in newborns, expected to launch in Q2 FY26.ICMR Proposes Ban on Dr Reddy's Nimesulide Drug - 23 Apr, 2025
The ICMR has suggested a selective ban on Nimesulide, affecting Dr Reddy's Laboratories' leading brand, Nise, amidst a growing market for the drug.Dr Reddys Issues Class 1 Recall in US Market - 22 Apr, 2025
Dr Reddys Laboratories is recalling 4,010 bags of Levetiracetam 0.75% Sodium Chloride Injection in the US due to a labelling error. The recall is classified as Class 1, indicating potential serious health risks.Dr Reddy's Stock Shows Modest Gains - 18 Apr, 2025
Dr Reddy's Laboratories Ltd shares rose by 0.42% to Rs 1163, with a market capitalization of Rs 97,735 crores. The stock is fairly valued with a P/E ratio of 18, trading at a 17% discount from its 52-week high of Rs 1,420.20.Dr. Reddy's Laboratories Faces Challenges Amidst Growth Plans - 16 Apr, 2025
Dr. Reddy's Laboratories maintains a strong position in the U.S. generics market, focusing on complex generics. However, the stock has declined 8% over the past year, with unchanged EPS estimates for fiscal 2026. The company holds a Zacks Rank #3 (Hold).Dr Reddy’s Shares Rise Amid Denials and Acquisitions - 15 Apr, 2025
Dr Reddy’s Laboratories shares experienced a rise following the company's denial of workforce cut rumors and positive brokerage ratings. The company is also in discussions to acquire Sanofi's Lantus. Overall, the stock showed strong performance amid increased trading volume and positive financial indicators.Dr Reddy's Denies Workforce Cost Reduction Claims - 14 Apr, 2025
Dr Reddy's Laboratories has categorically denied media reports about a 25% workforce cost reduction, labeling them as factually incorrect. The company emphasized it does not comment on market speculations.Dr Reddy's Laboratories Implements Major Downsizing - 13 Apr, 2025
Dr Reddy's Laboratories is reducing workforce costs by 25%, potentially laying off 300-400 employees, primarily those in higher salary brackets. This move aims to offset margin pressures from declining Revlimid sales while maintaining operational efficiency and double-digit growth.Dr Reddy's Faces Tax Demand of Rs 2,396 Crore - 11 Apr, 2025
Dr Reddy's Laboratories received a show-cause notice from tax authorities demanding Rs 2,396 crore, linked to a tax issue from its 2022 merger with Dr Reddy's Holding Ltd.Dr Reddy's Reports Profit Amid Stock Decline - 10 Apr, 2025
Dr Reddy's Laboratories reported a Q3 net profit of Rs 27.9 crore, recovering from a loss last year. However, the stock fell 3.11% following the results amid broader pharma sector declines due to tariff concerns.Dr Reddy's Faces Tariff Concerns Amid IT Partnership - 09 Apr, 2025
Dr Reddy's Laboratories faces a 4% stock decline following Trump's tariff announcement on pharmaceuticals. Meanwhile, the company partners with Kyndryl to improve IT operations using AI technology.Dr. Reddy's Faces Tax Notice Amid Earnings Report - 05 Apr, 2025
Dr. Reddy's Laboratories reported a 14.7% revenue increase in Q3 FY25. The company also received a ₹2,395 crore tax reassessment notice related to a merger, asserting compliance with tax laws and plans to respond appropriately.Dr Reddy's Laboratories Faces Mixed Performance - 04 Apr, 2025
Dr Reddy's Laboratories shares have declined 19.5% YTD and 17% over six months, but long-term returns remain positive. Domestic sales are expected to grow 21% YoY, driven by the Sanofi portfolio integration, while US sales growth is projected at only 3% YoY in Q4FY25.Dr Reddys Shares Surge on US Tariff Relief - 03 Apr, 2025
On April 3, 2025, Dr Reddys Laboratories shares rose significantly as US President Trump excluded pharmaceuticals from new tariffs, leading to a 5% increase. The overall sentiment in the pharma sector was positive, with stocks opening higher and gaining throughout the day.Dr Reddy's Faces Margin Pressure from Tariffs - 02 Apr, 2025
Dr Reddy's Laboratories is likely to experience margin pressure due to potential tariff increases affecting export costs, particularly given its high reliance on the US market.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 7.31K Cr → 8.53K Cr (in ₹), with an average increase of 5.0% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.14% to 12.89% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 1.25K Cr → 1.41K Cr (in ₹), with an average increase of 11.2% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, DRREDDY stock has moved up by 2.0%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Mar 2025 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 26.85% to 25.75% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.22% to 10.15% in Mar 2025 quarter
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹7,672.70Cr as on June 2024 (Q2 24)
Net Profit: ₹1,392.40Cr as on June 2024 (Q2 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddy's Laboratories |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Dr Reddy's Laboratories
Check out the Mutual Funds with significant holdings in Dr Reddy's Laboratories.
Futures and Options
View the latest movement in Dr Reddy's Laboratories Futures & Options, including strike prices, expiry dates, and percentage changes.
FAQs
What is Dr Reddys Laboratories Ltd price today?
Dr Reddys Laboratories Ltd share price today stands at ₹1176, Open: ₹1204.4, Previous Close: ₹1198.7, High: ₹1204.4, Low: ₹1169, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.
How to Buy Dr Reddys Laboratories Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Dr Reddys Laboratories Ltd shares
What are today's traded volumes of Dr Reddys Laboratories Ltd?
Today's traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 16.63L.
What is today's market capitalisation of Dr Reddys Laboratories Ltd?
Today's market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹92,582.82 Cr.
What is the 52 Week High and Low Range of Dr Reddys Laboratories Ltd?
How much percentage Dr Reddys Laboratories Ltd is down from its 52 Week High?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1176. It is down -17.27% from its 52 Week High price of ₹1421.49
How much percentage Dr Reddys Laboratories Ltd is up from its 52 Week low?
Dr Reddys Laboratories Ltd (DRREDDY) share price is ₹1176. It is up 15.29% from its 52 Week Low price of ₹1020